- Ticker
- ABSI
- Price
- 4.38
- Stock movement up
- +0.13 (3.06%)
- Company name
- Absci Corp
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 406.69M
- Ent value
- 235.65M
- Price/Sales
- 280.09
- Price/Book
- 1.19
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -80.64%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2022-08-25
DIVIDENDS
ABSI does not pay dividends
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 280.09 |
| Price to Book | 1.19 |
| EV to Sales | 162.29 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 92.85M |
| EPS (TTM) | -1.00 |
| FCF per share (TTM) | -1.26 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.45M |
| Gross profit (TTM) | -4.38M |
| Operating income (TTM) | -92.89M |
| Net income (TTM) | -90.00M |
| EPS (TTM) | -1.00 |
| EPS (1y forward) | -1.24 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -301.86% |
| Operating margin (TTM) | -6397.59% |
| Profit margin (TTM) | -6198.21% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 226.00M |
| Net receivables | 350.00K |
| Total current assets | 255.96M |
| Goodwill | 21.34M |
| Intangible assets | 54.15M |
| Property, plant and equipment | 0.00 |
| Total assets | 395.46M |
| Accounts payable | 6.74M |
| Short/Current long term debt | 18.21M |
| Total current liabilities | 41.88M |
| Total liabilities | 54.96M |
| Shareholder's equity | 340.50M |
| Net tangible assets | 286.35M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -74.46M |
| Capital expenditures (TTM) | 38.54M |
| Free cash flow (TTM) | -113.00M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -26.43% |
| Return on Assets | -22.76% |
| Return on Invested Capital | -25.88% |
| Cash Return on Invested Capital | -32.50% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.25 |
| Daily high | 4.50 |
| Daily low | 4.25 |
| Daily Volume | 592K |
| All-time high | 30.29 |
| 1y analyst estimate | 15.50 |
| Beta | - |
| EPS (TTM) | -1.00 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| ABSI | S&P500 | |
| Current price drop from All-time high | -85.54% | -13.41% |
| Highest price drop | -89.67% | -56.47% |
| Date of highest drop | 12 Jul 2022 | 9 Mar 2009 |
| Avg drop from high | -68.24% | -11.38% |
| Avg time to new high | 46 days | 12 days |
| Max time to new high | 268 days | 1805 days |
COMPANY DETAILS
Marketcap
406.69M
Marketcap category
Small-cap
Description
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Employees
211
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
VANCOUVER, Wash. and NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand th...
September 1, 2022
VANCOUVER, Wash. and NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the...
August 24, 2022
Absci reported a net loss of $28.7 million a day after announcing a "strategic reorganization."
August 15, 2022
Absci Corporation (ABSI) delivered earnings and revenue surprises of 0% and 38.53%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
August 11, 2022
Exceeded annual Active Program guidance with ten programs signed year-to-date Executed strategic reorganization to extend cash runway into late-2025 VANCOUVER, Wash. and NEW YORK, Aug. 11, 2022 (GLOBE...
August 11, 2022
Biotech firm Absci announced an unspecified number of layoffs Tuesday, blaming "macroeconomic conditions" and the need to streamline operations. "The macro-economic conditions of the last few months ...
August 10, 2022
Absci, Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics are part of Zacks top Analyst Blog.
August 10, 2022
Risk and reward are the yin and yang of stock trading, the two opposite but essential ingredients in every market success. And there are no stocks that better embody both sides – the risk factors and ...
August 2, 2022
VANCOUVER, Wash. and NEW YORK, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the...
August 1, 2022
Birch Biosciences is bringing synthetic biology to plastic recycling to create a true circular plastic economy.
July 26, 2022
Next page